Sigurdis Haraldsdottir1, Heather Hampel2, Lai Wei3, Christina Wu1, Wendy Frankel4, Tanios Bekaii-Saab1, Albert de la Chapelle5, Richard M Goldberg1. 1. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA. 2. Division of Human Genetics, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA. 3. Center for Biostatistics, The Ohio State University Medical Center, Columbus, Ohio, USA. 4. Department of Pathology, The Ohio State University Medical Center, Columbus, Ohio, USA. 5. Molecular Biology and Cancer Genetics Program, The Ohio State University Medical Center, Columbus, Ohio, USA.
Abstract
PURPOSE: An increased risk of prostate cancer is currently not considered a part of the Lynch syndrome spectrum. The purpose of this study was to retrospectively examine prostate cancer incidence in the Lynch syndrome cohort at the Ohio State University in comparison with that in the general population. METHODS: We included all males diagnosed with Lynch syndrome from June 1998 to June 2012 at the Ohio State University and obtained baseline information including cancer history. If patients had not been seen in the 12 months before June 2012, they were contacted to document changes in their cancer history. We compared prostate cancer incidence among the Lynch syndrome families with that of the general population by using the Surveillance, Epidemiology, and End RESULTS registry 1999-2009. RESULTS: Of the 188 males identified with Lynch syndrome, 11 males were diagnosed with prostate cancer during the study period. The ratio of observed to expected numbers of prostate cancer cases resulted in a standardized rate ratio of 4.87 (95% confidence interval: 2.43-8.71). Impaired mismatch repair expression and microsatellite instability were seen in one out of two prostate cancer specimens available for testing. CONCLUSION: Males with Lynch syndrome had a nearly fivefold increased risk of developing prostate cancer but did not appear to have earlier onset or a more aggressive phenotype.
PURPOSE: An increased risk of prostate cancer is currently not considered a part of the Lynch syndrome spectrum. The purpose of this study was to retrospectively examine prostate cancer incidence in the Lynch syndrome cohort at the Ohio State University in comparison with that in the general population. METHODS: We included all males diagnosed with Lynch syndrome from June 1998 to June 2012 at the Ohio State University and obtained baseline information including cancer history. If patients had not been seen in the 12 months before June 2012, they were contacted to document changes in their cancer history. We compared prostate cancer incidence among the Lynch syndrome families with that of the general population by using the Surveillance, Epidemiology, and End RESULTS registry 1999-2009. RESULTS: Of the 188 males identified with Lynch syndrome, 11 males were diagnosed with prostate cancer during the study period. The ratio of observed to expected numbers of prostate cancer cases resulted in a standardized rate ratio of 4.87 (95% confidence interval: 2.43-8.71). Impaired mismatch repair expression and microsatellite instability were seen in one out of two prostate cancer specimens available for testing. CONCLUSION: Males with Lynch syndrome had a nearly fivefold increased risk of developing prostate cancer but did not appear to have earlier onset or a more aggressive phenotype.
Authors: Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan Journal: Science Date: 2005-10-28 Impact factor: 47.728
Authors: Christina M Bauer; Anna M Ray; Bronwen A Halstead-Nussloch; Robert G Dekker; Victoria M Raymond; Stephen B Gruber; Kathleen A Cooney Journal: Fam Cancer Date: 2011-03 Impact factor: 2.375
Authors: Aung Ko Win; Noralane M Lindor; Joanne P Young; Finlay A Macrae; Graeme P Young; Elizabeth Williamson; Susan Parry; Jack Goldblatt; Lara Lipton; Ingrid Winship; Barbara Leggett; Katherine M Tucker; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Julie Arnold; A Joan Levine; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; John L Hopper; Mark A Jenkins Journal: J Natl Cancer Inst Date: 2012-08-28 Impact factor: 13.506
Authors: Andrew M D Wolf; Richard C Wender; Ruth B Etzioni; Ian M Thompson; Anthony V D'Amico; Robert J Volk; Durado D Brooks; Chiranjeev Dash; Idris Guessous; Kimberly Andrews; Carol DeSantis; Robert A Smith Journal: CA Cancer J Clin Date: 2010-03-03 Impact factor: 508.702
Authors: Mala Pande; Chongjuan Wei; Jinyun Chen; Christopher I Amos; Patrick M Lynch; Karen H Lu; Laura A Lucio; Stephanie G Boyd-Rogers; Sarah A Bannon; Maureen E Mork; Marsha L Frazier Journal: Fam Cancer Date: 2012-09 Impact factor: 2.375
Authors: Victoria M Raymond; Bhramar Mukherjee; Fei Wang; Shu-Chen Huang; Elena M Stoffel; Fay Kastrinos; Sapna Syngal; Kathleen A Cooney; Stephen B Gruber Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: M Clendenning; L Senter; H Hampel; K Lagerstedt Robinson; S Sun; D Buchanan; M D Walsh; M Nilbert; J Green; J Potter; A Lindblom; A de la Chapelle Journal: J Med Genet Date: 2008-01-04 Impact factor: 6.318
Authors: Eli Marie Grindedal; Pål Møller; Ros Eeles; Astrid Tenden Stormorken; Inger Marie Bowitz-Lothe; Stefan Magnus Landrø; Neal Clark; Rune Kvåle; Susan Shanley; Lovise Maehle Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-09-01 Impact factor: 4.254
Authors: Jesse P Wright; Kathleen W Montgomery; Joshua Tierney; Jill Gilbert; Carmen C Solórzano; Kamran Idrees Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: Veda N Giri; Karen E Knudsen; William K Kelly; Wassim Abida; Gerald L Andriole; Chris H Bangma; Justin E Bekelman; Mitchell C Benson; Amie Blanco; Arthur Burnett; William J Catalona; Kathleen A Cooney; Matthew Cooperberg; David E Crawford; Robert B Den; Adam P Dicker; Scott Eggener; Neil Fleshner; Matthew L Freedman; Freddie C Hamdy; Jean Hoffman-Censits; Mark D Hurwitz; Colette Hyatt; William B Isaacs; Christopher J Kane; Philip Kantoff; R Jeffrey Karnes; Lawrence I Karsh; Eric A Klein; Daniel W Lin; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark J Mann; James R Mark; Peter A McCue; Martin M Miner; Todd Morgan; Judd W Moul; Ronald E Myers; Sarah M Nielsen; Elias Obeid; Christian P Pavlovich; Stephen C Peiper; David F Penson; Daniel Petrylak; Curtis A Pettaway; Robert Pilarski; Peter A Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Mark E Robson; Matt T Rosenberg; Howard Sandler; Oliver Sartor; Edward Schaeffer; Gordon F Schwartz; Mark S Shahin; Neal D Shore; Brian Shuch; Howard R Soule; Scott A Tomlins; Edouard J Trabulsi; Robert Uzzo; Donald J Vander Griend; Patrick C Walsh; Carol J Weil; Richard Wender; Leonard G Gomella Journal: J Clin Oncol Date: 2017-12-13 Impact factor: 44.544
Authors: Patrick G Pilié; Anna M Johnson; Kristen L Hanson; Megan E Dayno; Ashley L Kapron; Elena M Stoffel; Kathleen A Cooney Journal: Cancer Date: 2017-06-28 Impact factor: 6.860
Authors: Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375
Authors: Julie L Boyle; Andrew W Hahn; Ashley L Kapron; Wendy Kohlmann; Samantha E Greenberg; Timothy J Parnell; Craig C Teerlink; Benjamin L Maughan; Bing-Jian Feng; Lisa Cannon-Albright; Neeraj Agarwal; Kathleen A Cooney Journal: JCO Precis Oncol Date: 2020-03-04
Authors: Jennifer L Beebe-Dimmer; Ashley L Kapron; Alison M Fraser; Ken R Smith; Kathleen A Cooney Journal: J Clin Oncol Date: 2020-03-24 Impact factor: 44.544